e-learning
resources
Paris 2018
Tuesday, 18.09.2018
Studies on the mechanisms underlying airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Utility of drug reaction assessments for inhaled therapies in patients with chronic suppurative lung diseases: results from 5 years of drug reaction assessments
G. Rinaldi (London, United Kingdom), B. Dennis (London, United Kingdom), G. Houseley (London, United Kingdom), O. Shah (London, United Kingdom), M. Loebinger (London, United Kingdom)
Source:
International Congress 2018 – Studies on the mechanisms underlying airway disease
Session:
Studies on the mechanisms underlying airway disease
Session type:
Thematic Poster
Number:
4407
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Rinaldi (London, United Kingdom), B. Dennis (London, United Kingdom), G. Houseley (London, United Kingdom), O. Shah (London, United Kingdom), M. Loebinger (London, United Kingdom). Utility of drug reaction assessments for inhaled therapies in patients with chronic suppurative lung diseases: results from 5 years of drug reaction assessments. 4407
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Aspirin inhalation treatment for COPD patients: Preliminary studies on PK and inflammatory biomarkers
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Changes in inhalation therapy after combined assessment of COPD
Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction
Year: 2015
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment?
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Methodological issues in therapeutic trials of COPD
Source: Eur Respir J 2008; 31: 927-933
Year: 2008
Effect of breathing parameters on lung dose in case of two combination drugs used in asthma and COPD therapy
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
Long-term safety of bilateral targeted lung denervation in patients with COPD in a single procedure
Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more
Year: 2015
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021
Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Are current treatment recommendations suited to elderly patients with asthma or COPD?
Source: Eur Respir Mon; 2009: 43: 267–285
Year: 2009
Based on what parameters of clinical remission should inhaled corticosteroids be stopped in children with asthma?
Source: Annual Congress 2013 –The best of paediatric asthma and allergy
Year: 2013
Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD
Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers
Year: 2006
An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations
Source: International Congress 2019 – Severe acute asthma and troublesome wheezing
Year: 2019
The parameters that may affect inhalation therapy success in elderly COPD and asthma patients
Source: International Congress 2015 – Co-existing diseases and asthma
Year: 2015
Compliance with nebulized therapy in patients with chronic lung disease
Source: Eur Respir J 2001; 18: Suppl. 33, 59s
Year: 2001
Effect of high or low-medium accumulated dose regimes of systemic corticosteroids for hospitalised patients with exacerbated chronic obstructive pulmonary disease: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021
Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial
Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD
Year: 2005
Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008
Inflammatory biomarkers in the evaluation of two-year outcomes of omalizumab treatment in severe allergic asthma.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Predicting treatment outcomes following an exacerbation of airways disease
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept